Business
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of
About this update from Vanda Pharmaceuticals Inc.
[{"type":"text","content":"WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the \"Court\") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. (\"Teva\") and Apotex Inc. and Apotex Corp. (\"Apotex\") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed.\n\n \n \n \n \n \n \n\n \nVanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the \"Defendants\"). The Defendants moved for judgment on the pleadings in April 2023. On June 27, 2024, the Court denied the motions. The Court concluded that the issues of patentability were not the same as those resolved in prior patent-infringement litigation between the parties. It further concluded that the Defendants raised issues that require claim construction and fact development before the Court can resolve the case.\nVanda intends to proceed with discovery in the case to continue pursuing its claims. Vanda will request relief from the Court that includes an order requiring the Defendants to discontinue marketing their generic versions of HETLIOZ® until the expiration of the patent-in-suit and enjoining them from the commercial manufacture, use, import, offer for sale and/or sale of these products.\nAbout Vanda Pharmaceuticals Inc.\nVanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.\nAbout HETLIOZ®\nFor full U.S. Prescribing Information for HETLIOZ®, including indication and Important Safety Information, visit www.hetlioz.com.\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\nVarious statements in this press release, including, but not limited to statements regarding Vanda's intentions to proceed with discovery in pursuit of its claims and to request relief from the Court, are \"forward-looking statements\" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes...